EMA/236601/2023

European Medicines Agency decision

P/0210/2023

of 14 June 2023

on the acceptance of a modification of an agreed paediatric investigation plan for deferoxamine (mesylate) / histidine / tryptophan / aspartic acid / n-acetyl-histidine (monohydrate) / glycine / alpha-ketoglutaric acid / arginine / potassium chloride / magnesium chloride (hexahydrate) / calcium chloride (dihydrate) / sodium chloride / alanine / 3,4-dimethoxy-N-methylbenzohydroxamic acid (EMEA-002735-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0210/2023

of 14 June 2023

on the acceptance of a modification of an agreed paediatric investigation plan for deferoxamine (mesylate) / histidine / tryptophan / aspartic acid / n-acetyl-histidine (monohydrate) / glycine / alpha-ketoglutaric acid / arginine / potassium chloride / magnesium chloride (hexahydrate) / calcium chloride (dihydrate) / sodium chloride / alanine / 3,4-dimethoxy-N-methylbenzohydroxamic acid (EMEA-002735-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0228/2021 issued on 9 June 2021,

Having regard to the application submitted by Dr. Franz Köhler Chemie GmbH on 20 January 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 April 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for Deferoxamine (mesylate) / histidine / tryptophan / aspartic acid / n-acetyl-histidine (monohydrate) / glycine / alpha-ketoglutaric acid / arginine / potassium chloride / magnesium chloride (hexahydrate) / calcium chloride (dihydrate) / sodium chloride / alanine / 3,4-dimethoxy-N-methylbenzohydroxamic acid, concentrate and solvent for solution for infusion, intracoronary use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Dr. Franz Köhler Chemie GmbH, Werner-von-Siemens-Str. 14-28, 64625 - Bensheim, Germany.

EMA/PDCO/44202/2023
Amsterdam, 26 April 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002735-PIP01-19-M01

Scope of the application

Active substance(s):

Deferoxamine (mesylate) / histidine / tryptophan / aspartic acid / n-acetyl-histidine (monohydrate) / glycine / alpha-ketoglutaric acid / arginine / potassium chloride / magnesium chloride (hexahydrate) / calcium chloride (dihydrate) / sodium chloride / alanine / 3,4-dimethoxy-N-methylbenzohydroxamic acid

Invented name and authorisation status:

See Annex II

Condition(s):

Cardioplegia

Pharmaceutical form(s):

Concentrate and solvent for solution for infusion

Route(s) of administration:

Intracoronary use

Name/corporate name of the PIP applicant:

Dr. Franz Köhler Chemie GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Dr. Franz Köhler Chemie GmbH submitted to the European Medicines Agency on 20 January 2023 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0228/2021 issued on 9 June 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 27 February 2023.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Cardioplegia

2.1.1. Indication(s) targeted by the PIP

For induction of cardioplegia in paediatric patients of all ages undergoing cardiac surgery to correct congenital heart malformation in operations requiring cardiopulmonary bypass support.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate and solvent for solution for infusion

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable.
Non-clinical studies	**Study 1 (FKC-001_02_rat_tox_iv)** Single dose intravenous toxicity study of 3,4-dimethoxy-N-methylbenzohydroxamic acid in rats. *This study is identical with Study 1 in EMEA-002735-PIP03-20 for the condition: Heart transplantation.* **Study 2 (FKC-003_01_dev_reprotox Rat)** Reproductive toxicity study of 3,4-dimethoxy-N-methylbenzohydroxamic acid in rats. *This study is identical with Study 1 in EMEA-002735-PIP03-20 for the condition: Heart transplantation.*
Clinical studies	**Study 3 (CL-N-HTX-Paed-II/10/20)** Randomised single-blind study to investigate the safety and the cardioprotective effects of custodiol-N to those of its precursor product in children from birth to less than 18 years of age undergoing heart surgery with cardiopulmonary bypass

Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By July 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.